Methods: Patients less than 30 years of age with Ewing sarcoma metastatic at diagnosis and normal organ function were enrolled on P9457, a study of maximally intensi ed alkylator therapy administered without stem cell support. Cycles included alternating courses of ifosfamide, etoposide and vincristine, doxorubicin and cyclophosphamide. Amifostine was given to a randomized one-half of ____patients entered in the last half of the study. The dosage administered was 825 mg/m2 15 minutes prior to, and 3 hours after the beginning of each dose of ifosfamide or cyclophosphamide, with premedications and precautions as previously described. Days ANC <500/ul, platelets >50,000/ul and between cycles were analyzed at weeks 6, 12 and 18 of therapy. Results: There was no signi cant difference seen in the arithmetic mean number of days with platelet count < 50,000/ul: 31 with amifostine, 30 without amifostine (Wilcoxon rank sum test, pvalue: 0.38), the arithmetic mean number of days with absolute neutrophil count < 500/ul: with amifostine, 31 days, without amifostine, 30 days (WRS, p = 0.14), or the number of days until the next chemotherapy cycle: with amifostine: 30 days, without amifostine, 29 days (p= 0.45) Conclusions: In the dose and schedule used, amifostine did not provide myeloprotection from the toxicity of high dose alkylator therapy, and did not shorten the interval until the administration of the next chemotherapy cycle.
Objectives: The expression of CD44 has been identi ed as prognostic factor in several malignant diseases. However, only few data exist correlating CD44 expression in soft tissue sarcoma with subsequent tumor progression or recurrence. The purpose of this study was to investigate the clinical signi cance of CD44s in adult soft tissue sarcoma (STS). Methods: Tumor specimens of 62 patients with STS were evaluated regarding CD44s expression using immunohistochemistry. The signi cance of the proposed prognostic indicators was evaluated in relation to survival and local recurrence. Results: Of 62 analyzed specimens, 49 tumors were CD44s positive compared to 13 CD44s negative tumors. Kaplan-Meier survival analysis indicated signi cantly better survival among patients whose tumor was CD44s positive (P = 0.015). Variables predictive of longer survival included resection quality (R0, P < 0.01) and tumor size (T1, P = 0.02). CD44s expression correlates with prognosis of soft tissue sarcomas. Conclusions: CD44s may play a pathogenetic role in tumor progression Determining the expression of CD44s in primary STS could be a valuable tool for selecting patients for further adjuvant treatment. Nevertheless, radical resection at initial surgery plays the pivotal role in soft tissue sarcoma treatment. Objectives: Irradiation of the growth plate during treatment of extremity sarcomas in pediatric patients often leads to undesirable late sequelae. Growth plate PTHrP has been reported to be downregulated following irradiation. The purpose of this project was to test the hypotheses that PTHrP rebounds as part of the normal response following growth plate irradiation and that a proven radioprotectant may act to enhance this PTHrP response. Methods: Sixty weanling 5 week Sprague-Dawley rats underwent right knee irradiation with single fraction 17.5 Gy while the left leg served as internal control. Twelve animals (half pretreated with amifostine) were euthanized at each of 0.5, 1, 2, 3, and 4 weeks. Immunohistochemical staining was performed and analyzed on tissue specimens for 3 animals per group per time for PTHrP, Bcl-2, Bax, caspase, TGF-beta and FGF-2. Results: Irradiated tissue demonstrated reduced staining for PTHrP early, but by 2 weeks after irradiation there was a notable return in PTHrP expression to at least control levels. This postirradiation PTHrP response was blunted rather than enhanced by amifostine. Amifostine showed its most dramatic effects in reducing Bax expression. Amifostine did not increase proliferative cytokines.
CTOS abstracts S75

POSTER PRESENTATIONS
Conclusions:
The observed PTHrP response corresponds to improving growth plate morphology and growth rate, suggesting a role for PTHrP in response to growth plate irradiation. Amifostine appears to decrease apoptosis mediators. This suggests a potential role for complementary radioprotectants that increase or maintain the post-irradiation PTHrP levels, such as pentoxifylline, as a means of maximizing growth plate recovery following irradiation. Objectives: To evaluate the outcome for giant cell tumor of bone treated with radiation therapy, with or without surgical resection. Methods: A retrospective review of 25 consecutive patients with pathologically con rmed giant cell tumor of bone receiving radiation therapy. Results: The anatomic distribution of lesions was as follows: cervical spine, 3; temporal bone, 1; thoracic or lumbar spine, 9; sacrum, 8; iliac, 1; and one each in the humerus, radius, and 1st metacarpal bone. Tumor size ranged from 2-20 cm (median, 9.5 cm). Twelve patients were referred with recurrent disease having undergone one or more prior surgical resections or had been heavily pretreated using chemo-embolization with subsequent recurrence. Fourteen patients were treated for gross disease, the remaining eleven were treated after gross total surgical resection. The dose for radiation was 46 Gy (range 25-65 Gy). Median follow up was 8.8 years (0.67-34 years). The actuarial 5-year OS and DFS were 91% and 58%, respectively. The actuarial 5-year LC and DMFS rates were 62% and 81%, respectively. Univariate analysis suggested that treatment for recurrent disease correlated with an inferior DFS (33% vs. 83%, p=0.06), DMFS (64% vs. 100%, p=0.08), and LC rate (42% vs. 83%, p=0.08) at 5 years. Additionally, there was an inferior OS rate in those patients treated with radiation alone (80% vs. 100%, p=0.04). Conclusions: Primary GCT of bone is a radiosensitive tumor. Radiation should be considered as an adjuvant to surgery or as an alternative in cases where excision would result in signi cant functional de cits. Objectives: Amifostine, a selective free-radical scavenger, is the only previously documented drug to achieve radioprotection of the growth plate, but its effect is incomplete. The aim of this pilot is to determine if any of four novel radioprotectant drugs other than amifostine can individually preserve the integrity of, or minimize damage to, physeal longitudinal growth during single radiation dose exposure in an animal model. Methods: Eighty-four weanling male Sprague-Dawley rats were randomized into 16 groups of 4-6 animals. All groups received single 17.5 Gy radiation exposure to the right knee with the left serving as control. Groups IA-C received pentoxifylline 50, 200, and 300 mg/kg. Groups IIA-B received selenium selenite 1.5 and 5 mg/kg. Groups IIIA-E received IL-1b 5, 15, 50, 125, and 500 mcg/kg. Groups IVA-E received misoprostol 0.1, 0.5, 1, 0, and 5 mg/kg. Group V received irradiation alone. At 6 weeks femoral and tibial lengths were measured and limb length percentage differences calculated between irradiated and unirradiated limbs. ANOVA was employed with alpha 0.05. Results: The radiation dose of 17.5 Gy caused a mean femoral length discrepancy of 21.1%. Pentoxifylline at the lowest dose reduced mean femoral limb discrepancy to 15.3% (p=0.0001). Higher doses were less effective. IL-1beta at 15 mcg/kg reduced femoral mean length discrepancy to 16.7% (p<0.0001). Selenium and misoprostol demonstrated dose-dependent effects, the highest dose for each resulting in 17.2% discrepancy (p<0.03). Conclusions: At speci c doses, each of the four tested drugs, administered prior to a single irradiation dose, signi cantly reduced limb length discrepancy in our animal model. Objectives: We describe three tumorigenic murine cell lines, which have a p53 de cient osteoblast-like cell as a common precursor. Methods: MMC2, p53-/-osteoblast-like cell line, was innoculated subcutaneously into athymic mice. Cells isolated from tumors were cultured in vitro. These cells were assayed for growth properties in vitro and tumorigenicity in nude mice . Expression of osteoblast-related genes were examined by Northern blotting. Results: Tumors developed in 3 out of 8 sites, and polyclonal cell lines were established from each tumor, and designated as MMOS1, MMOS2 and MMOS3. Expression patterns of the osteoblast-related genes were correlated well with the features of the original tumors, ranging from an osteoblastic osteosarcoma (MMOS2) to tumors with scarce or no osteoid formation (MMOS1 and MMOS3). Properties as malignant cells also varied among the three cell lines. MMOS1, which showed the slowest growth in a low-serum condition, developed markedly larger tumors in vivo than the other two cell lines. MMOS3 showed the fastest growth in a low-serum condition and produced the largest number of colonies in soft agar, but did not develop lung metastases, whereas MMOS1 and MMOS2 developed lung metastases with a frequency of 30% and 50%. Because these three cell lines have a common precursor, the heterogeneity among them is clearly attributed to genetic alterations that took place during transformation process, and therefore these cell lines will be suitable materials to isolate the responsible genes.
In Objectives: Clear cell sarcoma (CCS) is a rare soft tissue sarcoma. We sought to determine prognostic indicators and effective treatment methods. Methods: We completed a retrospective review of the Massachusetts General Hospital and Children's Hospital, Boston, records identifying 21 patients. We completed a systematic review of the English literature identifying 283 patients with clinical data from 83 articles. The cumulative database was used to evaluate patient demographics, prognostic factors, and the effect of external beam radiation. Results: Common locations were foot/ankle, 38.7 percent, knee, 12.4 percent, and wrist/hand, 12.4 percent. Common metastatic sites were lymph nodes and the lung. Overall 5 year survival was 48.6 percent. Metastasis at presentation was a prognostic indicator with 5 year survival of 13 percent vs 55 percent (p <0.0001). Tumor size less than 5 cm was prognostic with 5 year survival rates of 30 percent vs 67 percent (p < 0.0001). 15 patients received external beam radiation for their primary tumor. All 15 had a surgical resection, were metastasis free at diagnosis, and did not receive chemotherapy. These patients received an average of 59.9 Gy. A control group of 100 patients with no radiation therapy but similar demographics (age, tumor size, primary tumor, and metastatic free at diagnosis) and treatment (surgical resection without chemotherapy) was identi ed. Fewer patients treated with radiation developed metastasis (13 vs 43 % p < 0.05) or died from disease (13 vs 43 % p< 0.05). Conclusions: CCS tends to occur in young adults, in distal locations and metastasize to lymph nodes and lung. Tumor size equal or greater than 5 cm and metastasis at diagnosis are poor prognostic indicators. External beam radiation is an effective adjuvant for primary CCS therapy. Objectives: Chondromodulin-1(ChM1) is a glycoprotein that inhibits angiogenesis and the expression is restricted to cartilage and eye. In cartilageous tumors, the expression of ChM1 was observed only in benign lesions, suggesting the role of loss of ChM expression during the malignant transformation (Hayami, et al. FEBS letter, 2001) . No information, so far, has demonstrated concerning the expression of ChM1 in osteosarcomas (OS), and here we report that some OS express the ChM1, which may relate to the origin of tumor cells. Methods: Using RT-PCR, the expression of mRNA of ChM1 in 26 cases of osteosarcoma tissues and 7 lines of osteosarcoma cell lines were analyzed. Results: The mRNA expression of the ChM1 was observed in 10 out of 26 OS, most of which were subclassi ed as chondroblastic OS. Among seven OS cell lines, the expression of ChM1 was observed in two, one of which was established from a chondroblastic OS.Tumors positive for the ChM1 expressed the type II and IX collagen, and aggrecan genes, as well as the osteocalcin genes, suggesting the bidirectional differentiation potential of these tumor cells. Treatment of ChM1 negative OS cell lines with 5-azadeoxy-cytidine induced the expression of the ChM1 gene in two cell lines. Bisul te sequencing demonstrated the methylated CpG residues in the critical promoter lesion in these cell lines, which were not methylated in human normal cartilage cells. Conclusions: These data suggest that some OSs stem from the mesenchymal cells with bidirectional potential, and epigenetic mechanisms may take a part in the process of cell fate determination. Results: Eighty-six-patients with histologically con rmed MFH (G1: n=8, G2: n=23, G3: n=55) were analysed. Local recurrence was 36% after a median of 13 months. Distant metastases occurred in 29% of patients. After a mean follow-up of 5.5 years, 42 patients were alive without evidence of disease, median survival time was 68 months at a cumulative 5-year survival rate of 65%. Tumour size signi cantly in uenced disease free survival (T2 vs. T1, P < 0.01, risk ratio [RR] 5.5), as did tumour depth (subfascial tumours, P = < 0.01, RR 3.3), and presence of lymph nodes (P = 0.02, RR 6.5). Positive microscopic margins and subfascial tumours were associated with an increased local recurrence rate (RR 5.7, P < 0.0001 and RR 3.5, P = 0.02, respectively).The only multivariate risk factors of distant metastases were tumour depth, in which patients with subfascial tumours fared worse (RR 4.0, P < 0.01) and tumour grade (RR 5.5, P = 0.03). Conclusions: We conclude that aggressive but limb preserving resection of MFH should be performed at initial operation to minimize risk of local recurrence; a strict follow-up especially of subfascial tumours should be performed.
Proliferation And Apoptosis Are Independent Prognostic Parameters In Human Liposarcoma [Abstract ID: 53] free (n=25) or showed residual microscopic (n=25) or macroscopic (n=1) disease. Multiple variables for each patient, including age, sex, tumor size, grading and numbers of apoptotic and proliferating cells were determined. Immunocytochemistry was performed for semiquantitative analysis of representative paraf n embedded tissue sections. Monoclonal antibodies targeted to proliferating cell nuclear antigen and apoptotic nuclei (Tunelassay) were utilised. The results were correlated with the postoperative course of these patients Results: The median survival time was 10.2 years. Multivariate analysis revealed a signi cant correlation between survival and grading, apoptosis and proliferation (p < 0.05 each). Conclusions: These data indicate that in liposarcoma tumor cell apoptosis and proliferation are in addition to conventional grading of strong prognostic value in the assessment of disease-speci c survival. Objectives: Introduction Suspension of the humeral head from the clavicle after total scapular resection is compared to endoprosthetic scapular reconstruction. The surgical technique of endoprosthetic reconstruction and functional results are described. Patients: 23 patients with scapular tumors requiring total scapular resection were treated. Resection included 12 total scapulectomies and 11 en-bloc resections of the scapula and humeral head. Seven patients received endoprostheses. Four had prosthetic humeral heads suspended from the clavicle and 12 had suspension of the native humeral head. All patients were followed more than 2 years. Methods: Endoprosthetic Surgical Technique Patient selection was crucial. All peri-scapular muscles were tumor-free. Resection was usually performed using a posterior approach. Most highgrade scapula tumors were resected with the proximal humerus. Smaller than a natural scapula, the prosthesis facilitated soft-tissue reconstruction and was multiply fenestrated for myodesis. It was placed on the serratus anterior and covered by the rhomboids, trapezius and latissimus. A curved humeral head prosthesis was cemented into the humerus and connected to the scapular prosthesis using Gore-tex™. Results: There were no deep wound infections, failures, or secondary amputations. Elbow range-of-motion and hand dexterity were similar. Patients with scapular endoprosthesis had better active abduction (60 -90 vs. 10 -20) . Patients with endoprosthetic reconstruction had a more natural contour. 6 patients with scapular prostheses (86%) and 10 patients with humeral suspensions (62%) had a good-to-excellent functional outcome. Conclusions: Scapular endoprosthesis reconstruction is associated with better functional and cosmetic outcomes compared to simple humeral head suspension from the clavicle. Objectives: The Histoculture Drug Response Assay (HDRA) is an in vitro chemosensitivity test that has a high correlation with clinical response, the usefulness of which has been reported in various kinds of solid tumors. In this study, in order to investigate the variation in chemosensitivity in STS, fresh biopsy or surgical samples of STS were tested using the HDRA methods. Methods: Eighty samples of fresh human STS were obtained during either the biopsy or surgical removal at Keio University Hospital in Japan between 1997 and 2001. As anti-tumor drugs, cisplatin (CDDP), doxorubicin (ADM), pirarubicin (THP), 4-hydroxy-ifosfamide (4-H-IFO) and etoposide (VP-16) were used. HDRA was performed according to the method previously reported. Results: Drug sensitivity testing by HDRA showed that two drugs, ADM and THP, had a signi cantly higher inhibitory rate than CDDP, IFOS, or VP-16 in the eighty soft tissue sarcomas tested. Depending on the morphological type, spindle cell sarcomas were sensitive to THP, which showed signi cantly higher inhibition rates than CDDP, IFOS, or VP-16. Small round cell sarcomas were relatively sensitive to all of the drugs tested. However the drug sensitivity of pleomorphic cell sarcoma was low except for ADM and THP, while its sensitivity to THP was higher than about 70%. Conclusions: Depending on the morphological type, STS showed various chemosensitivity in HDRA. However, there are numerous other soft tissue sarcomas that do not belong to these categories; drug sensitivity testing in each of them and the devising of individualized treatment strategies seems necessary to improve the therapeutic outcome. Objectives: To identify the incidence of a cortical breech on the initial presentation X-rays of patients with distal femoral GCTs, and whether this lead to a higher rate of local recurrence of tumour and increase in severity of surgery. Methods: A prospective database is kept of all patients seen in the unit, it contains data on over 10, 000 patients seen over 34 years. Using the database initial presentation X-rays on 54 patients with distal femoral GCTs were reviewed. The size of the tumour was estimated using a facility of the database, by measuring the largest dimensions of the tumour (depth, breadth & height). The volume of the distal femur was estimated using the same X-ray and computer programme. The X-rays were then carefully studied for evidence of a cortical breach on antero-posterior (AP) and lateral views. The records were also checked for evidence of subsequent locally recurrent disease and subsequent surgery. Results: X-rays were reviewed on 54 patients (29 male, 25 female), range of 18-72 years. All patients had a biopsy proven GCT of the distal femur, X-rays (prior to biopsy) were reviewed. 34 (63%) patients with a cortical breech on X-ray. The mean tumour volume : distal femoral volumes (TV:DFV) was statistically greater between those patients with a cortical breach and those without, using ANOVA (p<0.0001). There were 13 patients with local recurrent disease but no statistical difference in subsequent local recurrence rates between the two patient groups.There was also no statistical differences between the number of operations for those who presented with a cortical breach or without. There was no evidence that more radical surgery was required if a patient presented with a cortical breach. Conclusions: The risk of cortical breech in patients with GCTs of the distal femur is dependant upon the tumour volume to distal femur volume ratio. If the ratio is above 54% then present with a cortical breech on X-ray is likely, (95% con dence interval), conversely if the ratio is less than 44 % then a cortical breach is unlikely. There is no evidence those patients with a cortical breach have a higher rate of local recurrence, an increased number of operations or more radical surgery. 
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